Corporate Reputation of Pharma 2022
Based on the feedback of over 2,200+ patient groups worldwide, these analyses provides invaluable insights into how pharma companies are perceived by patient groups and how they can improve.
Pharma and ESG: the Patient Perspective
PatientView is launching its newest report in 2023, giving pharma companies important and impactful patient group insight into Environmental, Social and Governance issues across healthcare.
Bespoke Research Projects
PatientView undertakes research for various clients including patient groups, industry and regulators.
Being Patient Centric
In ‘Being Patient-Centric after a Pandemic’, 1,589 patient groups worldwide propose a new business model for patient centricity for 2022 onwards.
Using patients insights to move the industry forward
“Patients’ health always comes first, and which is why working with patient representatives as equal partners helps us to better understand and speak with one voice regarding the needs of patient communities as well as drive patient-centric innovations across our organization. Your insights and feedback from the PatientView survey truly help us to focus on areas that we can improve on to enable us to become better partners in your future.”Eva Bretschneider, Head, Patient Partnerships & Stakeholder Engagement, Bayer AG
“Building trust is essential to our partnerships with the communities we serve. PatientView helps us to understand the opinions of those we work alongside and how we can move closer to becoming a trusted partner. We know that we need to listen and learn and walk this journey together.
The insights generated are also critical for patient communities, allowing them to make informed decisions about which companies to collaborate with in order to improve the well-being of their communities.”Alex Kalomparis, Senior Vice President, Public Affairs, Gilead
“The voice of the patient is the driving force in everything we do at Horizon. PatientView’s study has provided us with valuable information around what is most important to patient groups and how Horizon can most effectively support them.
This study gives us a better understanding of what we are doing well and where we can improve as we work to address the needs of people impacted by rare, autoimmune and severe inflammatory diseases.”Matt Flesch, Vice President, Communications and Patient Advocacy, Horizon Therapeutics
The PatientView survey is a valuable instrument for pharmaceutical companies to measure how well they are meeting patients’ needs – and where there are gaps to address.
The annual global rankings by patient organizations give us insights about our performance across 10 patient-centric indicators, helping us to improve our interactions and offerings with patient organizations and the patients they represent.Jan Nissen, VP, Patient Innovation & Engagement, Merck & Co, Inc.
"At Pfizer, our purpose is focused on patients: breakthroughs that change patients’ lives. As Pfizer’s Vice President of Patient Advocacy, my role is to ensure that the patient voice is embedded at the core of everything we do and our colleagues around the world work hand in hand with patients, caregivers, and patient advocacy groups to meet the needs of patients everywhere, every day.
Your participation in the PatientView survey will help us better serve the needs of patients and advance our shared goal of helping our communities live longer, healthier and more productive lives."Emma Andrews, Vice President Patient Advocacy, Pfizer
What we do
We work with one of the most important forces in healthcare: the Patient Movement.
PatientView undertakes regular evidence-based research into the different perspectives of patient organisations around the world on a range of issues. PatientView’s reach among these patient organisations is unique, with as many as 40,000 such groups in our informal network.
Patient organisations are in a unique position to provide valuable insights since they are the only stakeholder to interact across every aspect of the healthcare system: from regulators, physicians, healthcare providers, healthcare payers, and of course patients. Patient organisations hold strong views not only about the experiences and needs of patients with whom they are familiar, but on their country’s healthcare policies and systems, the value of technologies (including digital and mobile), and even the reputational status of the various agencies that make healthcare. Across our 20 year history, PatientView has collated evidence-based feedback on all these important subjects. Today, our most high-profile product concerns the corporate reputation of the pharmaceutical industry (from the perspective of patient groups). The product helps pharma develop and improve their strategies to build robust relationships with their ultimate customers, patients - and of course patient groups.
The Annual Survey of patient groups' perception of the pharmaceutical industry.
Corporate Reputation 2022
Being Patient-Centric after a Pandemic
What patient groups need and expect from pharma. A toolkit with deep-dive reports.
Find out more
Quantitative survey assessing the strengths and weaknesses of the patient movement.
Find out more
What 2000+ patient groups worldwide say about pharma in 2022
May 2023: Now in its 12th year, PatientView’s Corporate Reputation of Pharma survey remains one of the few studies that explore the opinions of patient groups globally on whether pharmaceutical… Continue reading “What 2000+ patient groups worldwide say about pharma in 2022”
Powerful Patient Advocacy: Advocating for people with rare and undiagnosed diseases
February 2023: The role of patient advocacy groups has become more consequential as patients and their families take an active role in their care. However, in the case of rare… Continue reading “Powerful Patient Advocacy: Advocating for people with rare and undiagnosed diseases”
Canada Edition: The Corporate Reputation of Pharma in 2022
PatientView's latest performance report of the pharmaceutical industry during 2022 collates the views and opinions of 122 UK patient groups.